Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Eikon Therapeutics Inc.
Headquarters: Hayward, CA, United States of America
Website: https://eikontx.com/
Year Founded: 2019
Status: Private
BioCentury | Feb 28, 2025
Finance
Eikon draws $350M private round, holding off on public markets
Plus BridgeBio cancer subsidiary finds SPAC route to market, in an otherwise sleepy week for fundraising
BioCentury | Jun 14, 2024
Finance
How Foresite is investing its $900M fund during the ‘first era’ of AI-driven R&D
Weeks after the firm co-led Xaira’s $1B round, Michael Rome looks ahead at ‘big themes’
BioCentury | Jun 1, 2023
Deals
June 1 Quick Takes: Lonza expands ADC offering with Synaffix takeout
Plus: Owkin investing $50M to build cancer spatial omics consortium and updates from Pfizer, AbbVie, Eikon, Lexicon, Hookipa, AstraZeneca, CMS and more
BioCentury | May 9, 2023
Management Tracks
Hofmann named CEO at Vicinitas
Plus: New COO, CTO at Guardant, Scangos joins Voyager’s board, and updates from Mariana, Merck KGaA, CymaBay and more
BioCentury | Apr 13, 2022
Data Byte
Largest venture rounds of 1Q22
Last quarter’s top 10 venture financings raked in a combined $2.4 billion
BioCentury | Apr 1, 2022
Management Tracks
Reed, Maraganore to join Takeda’s board
Plus Merck’s Frazier joins Eikon as independent director, and updates from Transgene and Syapse
BioCentury | Mar 23, 2022
Management Tracks
Barr to succeed Baynes at Merck
After spearheading Keytruda’s development, next challenge for the pharma CMO will come at Eikon; plus updates from Mammoth, OraSure, Strata and Acacia
BioCentury | Jan 7, 2022
Finance
Eikon to double headcount with $518M series B
Roger Perlmutter-led super-resolution microscopy company has unveiled an expanded C-suite
BioCentury | Jun 29, 2021
Management Tracks
Ogilvy’s Cronin joins Moderna; plus Gates Foundation, Turning Point, Quanterix, Esperion, Eikon and more
Kate Cronin will join Moderna Inc. (NASDAQ:MRNA) as chief brand officer on July 12. Cronin was global CEO at Ogilvy Health, a part of WPP plc (NYSE:WPP). Emilio Emini will become interim CEO of the
BioCentury | Jun 5, 2021
Finance
How two new Foresite deals build on the firm’s investment in Relay, with computational tech and AI opening doors
Recent investments in Eikon, Interline continue push toward new data sets
Items per page:
1 - 10 of 14